Zosano Pharma Corp (NASDAQ:ZSAN) has been given an average broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the company, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy recommendation.
Analysts have set a 12 month consensus target price of $10.00 for the company, according to Zacks. Zacks has also given Zosano Pharma an industry rank of 79 out of 255 based on the ratings given to its competitors.
A number of research firms recently issued reports on ZSAN. Zacks Investment Research reaffirmed a “buy” rating and issued a $3.00 target price on shares of Zosano Pharma in a research report on Saturday, August 24th. ValuEngine upgraded Zosano Pharma from a “hold” rating to a “buy” rating in a report on Thursday, August 1st.
Shares of NASDAQ:ZSAN traded up $0.41 during midday trading on Friday, reaching $1.96. The company had a trading volume of 1,223,265 shares, compared to its average volume of 976,857. The company has a quick ratio of 1.22, a current ratio of 1.22 and a debt-to-equity ratio of 0.34. The business’s 50 day moving average price is $2.06 and its 200 day moving average price is $3.08. The stock has a market cap of $34.74 million, a PE ratio of -0.52 and a beta of 2.62. Zosano Pharma has a 1-year low of $1.41 and a 1-year high of $6.65.
Zosano Pharma (NASDAQ:ZSAN) last released its earnings results on Wednesday, August 14th. The biotechnology company reported ($0.55) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.01. On average, research analysts expect that Zosano Pharma will post -2.48 earnings per share for the current fiscal year.
Zosano Pharma Company Profile
Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics to patients suffering from migraine using its Adhesive Dermally-Applied Microarray technology. Its lead product candidate is M207, a proprietary formulation of zolmitriptan used for the treatment of migraine.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zosano Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma and related companies with MarketBeat.com's FREE daily email newsletter.